U.S. markets closed

Agenus Inc. (AGEN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.7100+0.0350 (+1.31%)
At close: 4:00PM EDT

2.6800 -0.03 (-1.11%)
After hours: 7:07PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.6750
Open2.7200
Bid2.6700 x 3100
Ask2.7100 x 1800
Day's Range2.5600 - 2.7400
52 Week Range2.2800 - 5.9500
Volume5,127,510
Avg. Volume3,822,088
Market Cap554.696M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-1.0500
Earnings DateMar 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • New Clinical Responses for AGEN1181 Presented at AACR
    GlobeNewswire

    New Clinical Responses for AGEN1181 Presented at AACR

    7 objective responses observed to date in multiple tumor typesNew responses reported in patients with melanoma and ovarian cancerBenefit seen in patients typically unresponsive to I-O agents LEXINGTON, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented new clinical data on AGEN1181, its next-generation anti-CTLA-4 antibody, at the American Association for Cancer Research (AACR) Annual Meeting from April 10 - 15, 2021. “The preclinical and translational data in conjunction with our updated clinical data with AGEN1181 alone or in combination with our PD-1, balstilimab, continue to strongly support and differentiate our next-generation CTLA-4 antibody,” said Steven O’Day, MD, Chief Medical Officer of Agenus. “AGEN1181 is showing activity in patients with tumors which typically do not respond to first-generation CTLA-4 and PD-1 antibodies. Equally important, the safety data continues to show no immune mediated hypophysitis, pneumonitis, or hepatitis to date. Given the efficacy and favorable safety profile, we have expanded AGEN1181 into Phase 2 in colorectal cancer patients as a first step in our efforts to expand to additional important cancer indications.” In two separate presentations at AACR, Agenus showcased the optimal performance of AGEN1181 in relevant models. In addition, as the clinical data matures, additional responses as well as a conversion from a partial response to a complete response, have been observed. The new data announced today include the following clinical responses: New partial response in the first melanoma patient treated (monotherapy)New conversion to complete response in ovarian cancer patient (AGEN1181 plus balstilimab)Partial response in microsatellite stable (MSS) colorectal cancer patient (AGEN1181 plus balstilimab)Partial response in PD-L1(-) ovarian cancer patient (AGEN1181 plus balstilimab) Partial response in MSS colorectal cancer patient (AGEN1181 plus balstilimab)Complete response in PD-L1(-) MSS endometrial cancer patient (monotherapy)Complete response by PET in PD-L1(-) MSS endometrial cancer patient (AGEN1181 plus balstilimab) Presentation Details:E-poster presentations were made available on the conference platform on April 10 at 8:30am ET. Posters with accompanying audio will be available for viewing to meeting registrants until June 21. Session: PO.IM02.10 - Therapeutic Antibodies, Including Engineered AntibodiesPoster title: Fc-enhanced anti-CTLA-4 antibody, AGEN1181: New mechanistic insights for potent antitumor immunity and combination potential in treatment-resistant solid tumorsAbstract number: 1878Presenting author: Antoine Tanne, PhD Session: PO.IM02.05 - Immune Monitoring / Clinical CorrelatesPoster title: Characterization of the pharmacodynamic activity of AGEN1181, an Fc-enhanced CTLA-4 antibody, alone and in combination with the PD-1 antibody balstilimabAbstract number: 1677Presenting author: Irina Shapiro, PhD In addition, Dr. Steven O’Day, Chief Medical Officer, Dr. Dhan Chand, Scientific Director, Head of Drug Discovery, and Dr. Jennifer Buell, President and COO, at Agenus, will participate in a webcast hosted by Dr. Matt Phipps of William Blair on Saturday, April 10, 2021 at 10:30 a.m. ET. Registration for the webinar can be done in advance at https://williamblair.zoom.us/webinar/register/WN_4tTw7GEFQPC2qC4B3TzrfQ. A replay will be available after the call on the Events & Presentations page of the Agenus website at https://investor.agenusbio.com/events-and-presentations. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential of AGEN1181 alone and in combination with other agents, as well as the potential to use such therapies in additional cancer indications. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. ContactAgenus Investor RelationsJan Medina, CFAAgenus781-674-4490Jan.Medina@agenusbio.com Agenus Media RelationsKimberly HaKKH Advisors917-291-5744kimberly.ha@kkhadvisors.com

  • Agenus to Participate in Webcast Hosted by William Blair on AGEN1181 and Balstilimab AACR Presentations
    GlobeNewswire

    Agenus to Participate in Webcast Hosted by William Blair on AGEN1181 and Balstilimab AACR Presentations

    LEXINGTON, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO, Dr. Steven O’Day, Chief Medical Officer, and Dr. Dhan Chand, Scientific Director, Head of Drug Discovery, at Agenus, will participate in a webcast hosted by Dr. Matt Phipps of William Blair on Saturday, April 10, 2021 at 10:30 a.m. ET. Dr. Steven O’Day will review abstracts presented at AACR 2021 featuring AGEN1181 and balstilimab, including objective responses observed in the ongoing Phase 1/2 trial, clinical benefits seen in underserved patient populations, and how they may inform the path forward for continued development. Dr. Jennifer Buell and Dr. Dhan Chand will also be available to discuss the Fc-engineering driving AGEN1181’s enhanced activity, and how the AACR presentations support AGEN1181’s place in the Agenus pipeline, alone and in combination with other immune-focused anti-cancer mechanisms. Registration for the webinar can be done in advance at https://williamblair.zoom.us/webinar/register/WN_4tTw7GEFQPC2qC4B3TzrfQ. A replay will be available after the call on the Events & Presentations page of the Agenus website at https://investor.agenusbio.com/events-and-presentations. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. Forward-Looking StatementsThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding clinical development plans and timelines, the therapeutic potential of AGEN1181 alone and in combination with other agents, as well as the anticipated presentation of updated clinical and preclinical data. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. ContactAgenus Investor RelationsJan Medina, CFAAgenus781-674-4490Jan.Medina@agenusbio.com Agenus Media RelationsKimberly HaKKH Advisors917-291-5744kimberly.ha@kkhadvisors.com

  • Agenus Inc (AGEN) Q4 2020 Earnings Call Transcript
    Motley Fool

    Agenus Inc (AGEN) Q4 2020 Earnings Call Transcript

    Thank you for standing by and welcome to the Agenus Fourth Quarter 2020 Conference Call and Webcast. With that said, I just want to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans and timelines as well as timelines for data release and partnership opportunities.